Long-term exposure to hypoxia inhibits tumor progression of lung cancer in rats and mice by Lunyin Yu & Charles A Hales
RESEARCH ARTICLE Open Access
Long-term exposure to hypoxia inhibits tumor
progression of lung cancer in rats and mice
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Abstract
Background: Hypoxia has been identified as a major negative factor for tumor progression in clinical observations
and in animal studies. However, the precise role of hypoxia in tumor progression has not been fully explained. In
this study, we extensively investigated the effect of long-term exposure to hypoxia on tumor progression in vivo.
Methods: Rats bearing transplanted tumors consisting of A549 human lung cancer cells (lung cancer tumor) were
exposed to hypoxia for different durations and different levels of oxygen. The tumor growth and metastasis were
evaluated. We also treated A549 lung cancer cells (A549 cells) with chronic hypoxia and then implanted the
hypoxia-pretreated cancer cells into mice. The effect of exposure to hypoxia on metastasis of Lewis lung carcinoma
in mice was also investigated.
Results: We found that long-term exposure to hypoxia a) significantly inhibited lung cancer tumor growth in
xenograft and orthotopic models in rats, b) significantly reduced lymphatic metastasis of the lung cancer in rats
and decreased lung metastasis of Lewis lung carcinoma in mice, c) reduced lung cancer cell proliferation and cell
cycle progression in vitro, d) decreased growth of the tumors from hypoxia-pretreated A549 cells, e) decreased Na
+-K+ ATPase a1 expression in hypoxic lung cancer tumors, and f) increased expression of hypoxia inducible factors
(HIF1a and HIF2a) but decreased microvessel density in the lung cancer tumors. In contrast to lung cancer, the
growth of tumor from HCT116 human colon cancer cells (colon cancer tumor) was a) significantly enhanced in the
same hypoxia conditions, accompanied by b) no significant change in expression of Na+-K+ ATPase a1, c)
increased HIF1a expression (no HIF2a was detected) and d) increased microvessel density in the tumor tissues.
Conclusions: This study demonstrated that long-term exposure to hypoxia repressed tumor progression of the
lung cancer from A549 cells and that decreased expression of Na+-K+ ATPase was involved in hypoxic inhibition of
tumor progression. The results from this study provide new insights into the role of hypoxia in tumor progression
and therapeutic strategies for cancer treatment.
Keywords: hypoxia, tumor growth, metastasis, A549 lung cancer cells, Lewis lung carcinoma, HCT116 colon cancer
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Background
Cancer is a major public health problem in the United
States [1] and many other countries in the world [2-4].
One in 4 deaths in the United States is due to cancer
[1]. Although much effort has been made and the over-
all cancer incidence rate has decreased in the most
recent time period, a total of more than 1.5 million new
cancer cases and more than half million deaths from
cancer are projected to have occurred in the United
States in 2010, of which lung cancer is the leading cause
of cancer death in both men and women [5].
Hypoxia which is often seen in solid tumors [6,7] has
been identified as a major negative prognostic factor
[8-19], because decreased availability of oxygen in the
tumor increases treatment resistance and favors tumor
progression and metastasis [15,20]. Development of
hypoxia in human solid tumors is due to rapid prolifera-
tion of tumor cells and the relative deficiency of blood
distribution in the tumor mass [15,20], resulting in low
oxygen levels in tumor cells, so-called hypoxic cells,
located at a distance from the blood vessels [20]. Tumor
* Correspondence: lyu3@partners.org
Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts
General Hospital, Harvard Medical School, Boston, MA 02114, USA
Yu and Hales BMC Cancer 2011, 11:331
http://www.biomedcentral.com/1471-2407/11/331
© 2011 Yu and Hales; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
hypoxia is an important factor in tumor biology which is
associated with angiogenesis, tumor cell aggressiveness,
metastasis and local recurrence [8,10,11,21].
In addition to observations from clinical data, animal
experiments have investigated the relationship between
tumor hypoxia and cancer progression. Investigators
have found that metastasis occurred significantly more
often in primary tumor tissues with high hypoxic frac-
tions [22], and that the more hypoxic cells present in
tumor tissue, the more lung and lymph node metastasis
occurred in mice bearing tumor [23]. They also found
that acute hypoxia influenced metastasis to a greater
extent than chronic hypoxia [23]. Studies have shown
that pretreatment of the cells with low oxygen induced
maximal lung metastasis [24] and that tumor hypoxia
was correlated with the number of metastatic lesions,
but not with tumor volume [25]. Studies have shown
that exposure to hypoxia significantly increased lung
metastasis in mice [26,27]. These studies also showed
that exposure to hypoxia significantly increased the
number of positive lymph nodes in mice, but not in
lung metastasis nodule [27,28]. A recent report showed
that systemic hypoxia promoted prostate cancer growth
in mice [29]. However, another study found no signifi-
cant change either in primary tumor growth or in lung
metastasis in a transgenic mouse breast cancer model
after exposing the mice to hypoxia [30]. Therefore, in
spite of much work done in different laboratories, the
precise role of hypoxia on tumor progression is far from
being completely understood [31].
Recently we unexpectedly found that hypoxia (10%
O2) strongly inhibited tumor growth of lung cancer in
nude rats. We therefore extensively investigated the role
of hypoxia in tumor progression in this study. We
hypothesized that hypoxia may not be a factor favoring
tumor progression of lung cancer.
Methods
Cancer cells
Human non-small cell lung carcinoma cell line A549
cells (A549 cells) and Lewis lung carcinoma cell line
LLC1 cells (established from the lung of a C57BL
mouse bearing a tumor) were purchased from ATCC
(American Type Culture Collection), Manassas, VA. The
A549 cells and LLC1 cells were grown in F-12K Med-
ium and in Dulbecco’s Modified Eagle’s Medium
(DMEM) respectively. In addition, human colon cancer
cell line HCT116 cells (HCT116 cells) and McCoy’s
modicum were also purchased from ATCC.
Animals
NIH nude rats (Cr:NIH-rnu), weighing ~ 150 g, were
obtained from the National Cancer Institute at Frederick
(NCI-Frederick, Frederick, MD). Male BABL/c nude
mice, 6 weeks old, were obtained from Charles River
Laboratories (Wilmington, MA). C57BL/6 mice, 8 to 10
weeks old, were supplied by Jackson Laboratory (Bar
Harbor, Maine). These animal experiments were
approved by the ethics committee for animal care of the
Subcommittee on Research Animal Care at Massachu-
setts General Hospital and had followed the USA Insti-
tutional Animal Care and Use Committee (IACUC)
guideline.
Hypoxia exposure
Animal exposure to hypoxia was performed as described
previously for our hypoxic pulmonary hypertension stu-
dies [32,33]. Briefly, the animals were weighed and
placed in a hypoxia chamber or exposed to normoxia
for a designed time. Oxygen concentration was main-
tained by the flow rates of compressed air and nitrogen.
Cage concentration of O2 was checked daily. The cages
were opened once a day to reduce CO2 concentration.
The animals were supplied with food and water ad
libitu during the experiments.
Subcutaneous xenograft models of lung cancer
Each animal was inoculated subcutaneously on the flank
with a single dose of 2 × 107 A549 cells in 200 μl of
phosphate-buffered saline solution, cell viability > 95%.
No Matrigel was used for this tumor cell injection. At
different time points (day 1, day 4 and day 7) after can-
cer cell injection, the animals were randomly divided
into normoxic and hypoxic groups for hypoxia exposure
for desired time. At end of the experiment, animals
were sacrificed and tumors were harvested. The same
procedures were performed for colon cancer using
HCT116 cells in this study.
Orthotopic rat model of lung cancer
A549 cells were orthotopically injected into the left lung
of rats according to published methods [34,35]. Briefly,
male nude rats were anesthetized with isoflurane by
using a rodent anesthesia machine. The rats were placed
in the right lateral decubitus position and an incision of
the skin was made to visualize the left lung. A single
dose of 2 × 107 A549 cells in 100 μl of phosphate-buf-
fered saline solution was injected into the left lateral
lung of the rats. Followed closure of the incisions with
sutures, the rats were turned to the left lateral decubitus
position until they had fully recovered at which time the
rats were returned to their cage. Four days after cancer
cell injection, the rats were placed in the hypoxia cham-
ber. After exposure to hypoxia for 10 days, the animals
were removed from the hypoxia chamber and tumors
were harvested. At the same time, mediastinal lymph
nodes were collected for evaluating the effect of long-
term exposure to hypoxia on lymphatic metastasis.
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Lung metastasis model of Lewis lung carcinoma
LLC1 cells (1 × 107 cells) were injected subcutaneously
into the left flank of male C57BL/6 mice according to
the method described previously [26,36]. On day 4 after
the tumor cell injection, the tumor volume was mea-
sured and then the animals were randomly divided into
normoxic and hypoxic groups. The mice for the hypoxic
group were placed in hypoxia chamber for 17 days. The
lung metastasis of Lewis lung carcinoma was assessed
according to methods described previously [26,36].
Briefly, the lungs were removed from sacrificed mice
and filled with Bouin’s fixative solution through trachea
and then immersed in the fixative. After 48 hours, the
number of metastatic foci on the lung surface was
counted with a dissecting microscope.
Hypoxia-pretreatment and tumor progression in mice
In order to investigate the effect of hypoxia on cultured
cancer cells in vitro and to determine the effect of
hypoxia-pretreatment on tumor growth in animals, we
carried out the following study. After seeding and
growth for a few hours under normoxia allowing to
attach to the bottom of flask, A549 cells were cultured
in a cell culture hypoxia chamber (0.5%O2/5%CO2/N2
balance) for seven days and then harvested for cell pro-
liferation assay, cell cycle analysis and biological analysis.
At the same time, other harvested cancer cells were
injected into nude mice subcutaneously (5 × 106/per
mouse). After three weeks under normoxia, the mice
were sacrificed and tumors were harvested. In addition,
HCT116 colon cancer cells were inoculated into mice
subcutaneously in this study with the same conditions
and procedures as used for the A549 cells to compare
the effect of chronic hypoxia on other type of cancers.
Measurement of tumor growth and evaluation of tumor
weigh
For the subcutaneous xenograft model, we used a
tumor growth curve based on tumor size for evaluation
of tumor growth during the period of experiment. The
tumor size (in cubic millimeters) was calculated
according to a formula (L × S2) × 0.5 (L = long dia-
meter of tumor, S = short diameter of tumor) [37]. In
addition, on the last day of the experiment, animals
were sacrificed with 200 mg/kg of pentobarbital and
used immediately for determination of tumor weight
and pathology as well as for biological analysis. Tumor
weight was determined by weighing the wet tumor.
Part of the tumor was fixed in 10% natural buffered
formalin, embedded in paraffin, sectioned at 4-6 μm
and stained with H & E or with immunohistochemistry
for pathological evaluation. The rest of the tumor tis-
sue was frozen immediately in liquid nitrogen for bio-
logical analysis.
Immunohistochemistry
Immunohistochemical staining with Ki67, a cell prolif-
eration marker, was performed to analyze cell prolifera-
tion. A percentage of Ki-67 positive cells expressed as
Ki67 proliferative index was estimated by calculating the
ratio of Ki-67 expressing cell nuclei to the total number
of cell nuclei in tumor tissues. TUNEL assay was con-
ducted by using TdT FragEL DNA Fragmentation
Detection Kit (Oncogene Research Products, San Diego,
CA), following the manufacturer’s protocol. An apopto-
tic index was determined by a blinded investigator by
counting the ratio of apoptotic cells to total cells in the
tissue section. In addition, CD31 antibody (Abcam,
Cambridge, MA) was used to detect tumor microvessel
density. The density was quantified by calculating the
number of CD31 positive microvessels under
microscope.
Mitosis analysis in tumor tissues
The number of mitotic cells in tumor tissues was
counted under H & E stained slides by a blinded pathol-
ogist. A mitosis index was calculated and expressed as
mitotic cell number/total cell number × 100.
Western blot analysis
Antibodies included HIF1a and Na+-K+ ATPase a1
(Sigma) and HIF2a and ß-actin (Santa Cruz Biotechnol-
ogy). Total proteins were isolated from tumor tissues and
cancer cells and Western blot was performed following our
previous work [37,38]. Briefly, homogenized tissues were
incubated on ice for 30 minutes in lysis buffer and then
centrifuged at 14,000 rpm for 10 minutes at 4°C. The
supernatant was removed and saved. Supernatants were
stored at -80°C until analysis. The protein concentration of
the lysate was determined by the Bio-Rad protein assay
(Bio-Rad Laboratories, Hercules, CA). Protein samples
were electrophoresed on SDS-polyacrylamide gel and then
transferred to polyvinylidene difluoride (PVDF) mem-
branes (Millipore Corporation, Bedford, MA). After an
overnight incubation with PBS with 10% nonfat milk, the
membrane was incubated with primary antibody for 1 hr
at room temperature or overnight at 4°C. The membrane
was washed with buffer and then incubated with a horse-
radish peroxidase linked secondary antibody for 1 hr at
room temperature. After being washed with buffer, the sig-
nals were detected using an enhanced chemiluminesence
(ECL) Western blot detection kit, Western Lightning (Per-
kinElmer Life Sciences, Boston, MA), and visualized by
exposure to X-ray film. Quantification of protein expres-
sion was performed using NIH 1.61 image software.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from tumor tissues using TRI-
zol reagent (Invitrogen, Carlsbad, CA) and RT-PCR was
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performed following our previous work [37-39]. Briefly,
total RNA (3 μg) was used to carry out RT-PCR to mea-
sure mRNA expression with Ready-To-Go Your-Prime
First-Strand Beads (Amersham Biosciences UK Limited,
Little Chalfront, Buckinghamshire, England) for reverse
transcription and Platinum PCR SuperMix reagents
(Invitrogen, Carlsbad, CA) for PCR according to the
manufacturer’s instructions respectively. The primer
pairs for HIF1a and for the housekeeping gene glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) were pur-
chased from Sigma Genosys, Woodlands, TX. After RT-
PCR, each sample was run in agarose gel (15.0 g/L) elec-
trophoresis to ensure that the right-size product was
amplified in the reaction. Bands were visualized using
ethidium bromide and the gels were photographed
under UV light. Quantification of RT-PCR products was
performed using NIH 1.61 image software.
Statistical Analysis
Statistics were performed using the computer program
Statview (SAS Institute Inc., Cary, NC) with t-Test. All
values were expressed as the mean ± SEM. Significance
was set at p < 0.05.
Results
Exposure to hypoxia inhibited lung cancer tumor growth
in nude rats
After injection with A549 cells subcutaneously, rats were
exposed to hypoxia for 14 days (Figure 1B). We found
that exposure to hypoxia significantly decreased the
growth of tumor from A549 cells (lung cancer tumor)
(Figure 2), showing decreased tumor size during hypoxia
exposure (Figure 2A) and reduced tumor weight (Figure
2B) as compared with the animals under normoxia.
Hypoxic animals showed a decrease in body weight (Fig-
ure 2C) and in food intake (Figure 2D). Hematocrit was
significantly increased in the hypoxic animals (Figure 2E).
We subsequently investigated the inhibitory effect
of different durations of hypoxia exposure on lung
cancer tumor growth in animals (Figure 1C). Four
days after cancer cell injection subcutaneously, a
tumor mass developed in the rats. After measuring
the tumor volume and randomly grouping the ani-
mals, we then exposed the animals bearing tumor to
hypoxia for 10 days and found that the tumor growth
was also significantly inhibited as compared with nor-
moxic controls (Figure 3A - E), showing significantly
decreased tumor size during hypoxia (Figure 3A) and
decreased tumor weight (Figure 3B) as well as the
ratio of tumor weight to body weight (Figure 3C).
Remarkably, almost all of the tumors from the nor-
moxia group were larger than those from hypoxic ani-
mals (Figure 3D). Hematocrit was significantly
increased in hypoxic animals (Figure 1E).
To further determine the effect of hypoxia on tumor
progression, we let the tumors grow in rat for 7 days
after cancer cell injection subcutaneously and then
exposed the rats to hypoxia for another 7 days (Figure
1D). We found that exposure to hypoxia for 7 days also
significantly inhibited the growth of lung cancer tumor
(Figure 3F &3G).
In addition to the subcutaneous xenograft model, we
used an orthotopic model of lung cancer to demonstrate
the effect of hypoxia on the tumor growth and lymph
node metastasis. We found that exposure to hypoxia for
10 days significantly inhibited the growth of lung cancer
tumor (Figure 3I) and reduced lymph node metastasis
(Figure 3J) in rats.
Figure 1 Experimental Protocols. (A) Animals in normoxia for 14 days after tumor cell injection. (B) Animals in hypoxia for 14 days after tumor
cell injection. (C) Animals in normoxia for 4 days after tumor cell injection and then in hypoxia for 10 days. (D) Animals in normoxia for 7 days
after tumor cell injection and then in hypoxia for 7 days. (E) Followed in normoxia for 4 days after tumor cell injection, animals were placed in
hypoxia for 10 days and then returned to normixa for another 7 days.
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Figure 2 Effect of hypoxia to hypoxia for 14 days on tumor growth of lung cancer in rats. After cancer cell injection, animals were
exposed to hypoxia (10% O2) for 14 days (Figure 1B). (A) Tumor growth curve, (B) Tumor weight, (C) Body weight, (D) Food intake and (E)
Hematocrit. * p < 0.05 as compared with normoxia. n = 6 for each group.
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Effect of normoxic recovery on hypoxic lung cancer
tumor growth in rats
We investigated if inhibition of the tumor growth was
reversed after recovery under normoxia in the subcuta-
neous xenograft model (Figure 1E). After hypoxia expo-
sure for 10 days, we moved the animals bearing lung
cancer tumor back to normoxia. We found that the pat-
tern of tumor growth was not changed immediately dur-
ing normoxic recovery, showing continued inhibition of
the tumor growth for several days (Figure 4A).
Effect of different levels of oxygen on lung cancer tumor
growth in rats
In order to determine which levels of oxygen most
impacted tumor growth, we used 10%, 12.5% and 15%
oxygen in the subcutaneous xenograft model. We found
that 10% oxygen maximally inhibited lung cancer tumor
growth after exposing animals to hypoxia for 10 days
(Figure 4B &4C). There was no significant inhibition of
the tumor growth under 15% oxygen.
Figure 3 Effect of hypoxia to hypoxia for 10 days or 7 days on tumor growth of lung cancer in rats.(A to E) Exposure to hypoxia for
10 days in xenograft model (Figure 1C) : (A) Tumor growth curve, (B) Tumor weight, (C) ratio of tumor weight to body weight, (D)
Distribution of tumor size (upper panel) and representative tumor samples (lower panel), (E) Hematocrit. *p < 0.05 as compared with normoxia.
n = 21 for normoxia group and 22 for hypoxia group. (F & G) Exposure to hypoxia for 7 days in xenograft model (Figure 1D): (F) Tumor
growth curve and (G) tumor weight. n = 5 for each group. *p < 0.05 as compared with normoxia. (H & I) Exposure to hypoxia for 10 days in
orthotopic model (Figure 1C): (H) Tumor weight and (I) lymph node number from orthotopic rats exposed to hypoxia for 10 days. *p < 0.05
as compared with normoxia. n = 5 for each group.
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Exposure to hypoxia inhibited lung metastasis of Lewis
lung carcinoma in mice
After 4 days of LLC1 cell injection subcutaneously, mice
were exposed to hypoxia for 17 days. We found that
hypoxia significantly inhibited lung metastasis of Lewis
lung carcinoma in mice (Figure 5 A-C). Not only was
the number of metastatic nodules in the lungs signifi-
cantly reduced in hypoxic mice (Figure 5A), but also the
size of the metastatic nodules was significantly
decreased (Figure 5B). We also found a significant inhi-
bition of primary tumor growth in hypoxic mice (Figure
5C).
Effect of hypoxia-pretreatment on lung cancer tumor
growth in mice
To determine if hypoxia-pretreatment affected tumor
growth, we exposed A549 cells to 0.5% O2 for 7 days
and then inoculated the cells into nude mice subcuta-
neously. First, we found that chronic hypoxia did not
stimulate A549 cell proliferation and cell cycle progres-
sion in vitro (Figure 6A &6B). We then found that
tumor growth from the hypoxia-pretreated lung cancer
cells was also not stimulated as compared with the
tumor from the cells without hypoxia-pretreatment (Fig-
ure 6C &6D).
Differential effect of hypoxia on colon cancer
To determine if long-term exposure to hypoxia
impacted tumor progression similarly in different types
of tumors, we investigated colon cancer by using the
same conditions and procedures. In contrast to lung
cancer, we found that long-term exposure to hypoxia
significantly stimulated the growth of tumor from
HCT116 cells (colon cancer tumor) in rats in the subcu-
taneous xenograft model (Figure 7A &7B). We also
found that HCT116 cell growth and cell cycle progres-
sion were significantly stimulated under hypoxia (0.5%
O2) (Figure 7C &7D) and hypoxia pretreatment signifi-
cantly increased colon cancer tumor growth in mice
(Figure 7E &7F).
Hypoxia inhibited cell proliferation, increased apoptosis
and decreased microvessel density in lung cancer tumors
To investigate the mechanism underlying hypoxia-
induced inhibition of lung cancer tumor growth, we
examined cell proliferation and mitosis as well as apop-
tosis in tumor tissues of lung cancer grown in rats that
exposed to 10% O2 for 10 days. We found a significant
decrease in expression of Ki67 (Figure 8A), a cell prolif-
eration marker, and in mitosis index (Figure 8B) in the
tumor tissues from hypoxic animals. We also found a
Figure 4 Normoxia recovery and different levels of oxygen on
lung cancer tumor growth in rats. Effect of normoxia recovery
on hypoxia-induced reduction of lung cancer tumor growth
(Figure 1E): (A) Tumor growth curve. Because large tumor mass
was not allowed in living animals, we sacrificed the control rats
when the tumor size reached over 1.5 cm. N = Rats under
normoxia for entire experiment. H+N = Rats under hypoxia for 10
days and then under normoxia for another 8 days. Effect of
different levels of oxygen on lung cancer tumor growth
(Figure 1C) (B & C): (B) Tumor growth curve and (C) Tumor weight.
n = 5 for each group. *p < 0.05 as compared with normoxia.
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significant increase in apoptosis in the tumor tissues
from hypoxic animals (Figure 8C).
Hypoxia inhibited expression of Na+-K+ ATPase in lung
cancer tumors, but not in colon cancer tumors
To determine the signaling pathway that affected lung
cancer growth under hypoxia, we examined expression
of Na+-K+ ATPase a1 subunit, which has been used as
a marker of Na+-K+ ATPase. We found a significant
inhibition of Na+-K+ ATPase a1 expression in tumors
from hypoxic rats (Figure 8D) and in A549 cells exposed
to hypoxia as well as in the tumor from the hypoxia-
pretreated A549 cells grown in mice (Figure 8E). How-
ever, no significant change in Na+-K+ ATPase a1
expression was observed in colon cancer tumor (Figure
8F).
Effect of long-term exposure to hypoxia on HIF
expression and microvessel density in lung cancer and
colon cancer tumors
We analyzed expression of HIF1a and HIF2a and used
this as an indicator of effective exposure to hypoxia. We
found significantly increased HIF1a protein expression
in hypoxic lung cancer tumor (Figure 9A) and colon
cancer tumor (Figure 9B). We also found a significant
increase in HIF2a expression in the lung cancer tumor,
but no HIF2a expression was detected in the colon can-
cer tumor (Figure 9C). In addition, tumor vascularisa-
tion was significantly affected by hypoxia exposure, but
the results were significantly different in lung and colon
cancer tumors. Compared with normoxic tumors, the
microvessel density was significantly decreased in
hypoxic lung cancer tumors (Figure 9D). However, the
microvessel density was significantly increased in colon
cancer tumors (Figure 9E). In addition, we measured
HIF1a expression in the hypoxic tumors from the rats
exposed to 12.5%O2 and 15%O2 found that 12.5%O2
significantly increased HIF1a expression, but no signifi-
cant change in HIF1a expression was observed in the
hypoxic tumor from animals exposed to 15%O2.
Discussion
It has been reported that hypoxia plays a critical role in
tumor progression. We in this study used different dura-
tions of hypoxia exposure, different concentrations of
oxygen, different species of animals and different type of
cancers to comprehensively investigate the effect of
hypoxia on tumor progression. We first exposed rats to
10% oxygen for 14 days after cancer cell inoculation and
found a significant inhibition of lung cancer tumor
growth. This result indicated that hypoxia exposure
inhibited lung cancer tumor development in vivo.
We further demonstrated that exposure to hypoxia
could decrease tumor growth even after the tumor had
already developed. A549 cells were inoculated into rats
and grown for 4 days. On the fourth day, the tumor was
palpable. We then placed the rats in the hypoxia cham-
ber. The tumor growth was also inhibited after exposure
to hypoxia. To confirm this result, we repeated this
experiment three more times, used more than 20 rats
for each group and obtained consistent results showing
a significant inhibition of the lung cancer tumor growth
in animals. Because hypoxic animals had a reduced body
weight gain as compared with the nomoxic rats, we
measured the ratio of tumor weight to body weight and
obtained similar results, showing decreased ratio of
tumor weight to body weight. Subsequently, we let the
tumor grow in rats for a longer time (7 days) before
exposure to hypoxia and found that the tumor growth
was still decreased. In order to determine if the same
condition of hypoxia affected other types of cancer
growth, we placed rats with colon cancer tumor in the
same chamber and found that the growth of colon can-
cer tumor was significantly stimulated. This result
Figure 5 Effect of hypoxia on lung metastasis of Lewis lung carcinoma in mice. On the fourth day after cancer cell injection, the animals
were placed under 10% hypoxia for 17 days (total of 3 weeks). After hypoxia exposure, the mice were sacrificed and lung metastasis nodules
were counted. (A) Number of metastatic nodules in mouse lungs, (B) Representative lungs showing metastatic nodules the lungs. More and
bigger metastasis nodules were seen in hypoxic mouse lungs than in normoxic lungs (arrows). (C) Quantitative data on primary tumor weight.
*p < 0.05 as compared with normoxia. n = 10 mice for each group.
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indicated that oxygen impacted lung cancer differently
from other cancers. Interestingly, Kallimaki et al. [30]
showed no significant change either in primary tumor
growth or in lung metastasis in a transgenic mouse
model of breast cancer after exposing the mice to
hypoxia for 6 weeks. Kulish et al. [40] found that high-
altitude hypoxia significantly inhibited growth of Guerin
carcinoma and sarcoma 45 and increased the anti-tumor
effect of chemotherapeutics on those tumors in albino
rats. Terraneo et al. reported that exposing mice xeno-
grafted with a tumor of LNCaP prostate cancer under
10% O2 for 28 days significantly increased the tumor
growth [29].
In previous studies, different concentrations of oxygen
were used in different laboratories, from 2% O2 to 10%
O2 [22,24,26,29]. To define the effect of different levels
of oxygen on tumor growth, we used physiologically
tolerated levels of 10%, 12.5% and 15% oxygen in this
study. Our results showed that, except 15%, both 10%
and 12.5% oxygen significantly decreased the tumor
growth, in which 10% oxygen showed a greater inhibi-
tion than 12.5%. To determine if normoxia recovery
increased or reversed tumor growth after hypoxia expo-
sure, we housed rats with tumor in normoxia after
removing them from the hypoxia chamber. We found
that the inhibition of tumor growth of lung cancer per-
sisted for almost a week after the rats were removed
from hypoxia. In addition, we exposed A549 cells to
0.5% oxygen for 7 days and then inoculated the cells
into mice. The mice were then housed under normoxia
for three weeks, which avoided the influence of hypoxia
on animals, such as reduced food intake and body
weight loss. The growth of tumor from hypoxia-pre-
treated A549 cells were still not stimulated in those
Figure 6 Effect of hypoxia on lung cancer cell proliferation and cell progression in vitro and hypoxia-pretreatment on tumor growth
in mice. A549 cells were cultured in 0.5% hypoxia for 7 days and then harvested for cell proliferation assay and cell cycle progression analysis.
In addition, the harvested cancer cells were inoculated into nude mice subcutaneously. After 21 days, the animals were sacrificed and the
tumors were collected. (A) Cell growth assay and (B) cell cycle progression analysis in vitro (n = 9 for each group); (C) Tumor growth and (D)
Tumor weight in mice. n = 7 for each group.
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Figure 7 Hypoxia exposure and colon cancer tumor growth.(A & B) Effect of hypoxia on colon cancer tumor growth (Figure 1C): Four
days under normoxia after HCT116 colon cancer cell injection, animals were exposed to hypoxia (10% O2) for 10 days from xenograft model
(protocols Figure 1C). (A) Tumor growth curve and (B) Tumor weight. *p < 0.05 as compared with normoxia. n = 6 rats for each group. (C to F)
Effect of hypoxia-pretreatment on colon cancer tumor growth: HCT116 cells were cultured in 0.5% hypoxia for 7 days and then harvested
for cell proliferation assay and cell progression analysis. In the meantime, the harvested cancer cells were inoculated into nude mice
subcutaneously. After 21 days, the animals were sacrificed and the tumors were collected. (C) Cell growth assay and (D) cell cycle progression
analysis in vitro (n = 9 for each group); (E) Tumor growth and (F) Tumor weight in mice. n = 5 for each group. *p < 0.05 as compared with
normoxia.
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Figure 8 Cell proliferation, apoptosis and Na+-K+ ATPase expression in lung cancer tumors. Immunohistochemistry was used to evaluate
cell proliferation and apoptosis. Mitosis was analyzed in slides with H & E stain. (A) Percent Ki67 positive cell number for cell proliferation; (B)
Mitosis index and (C) Apoptosis. Left panel showing quantitative data and right panel showing representative micrographs. n = 5 for each
group. Expression of Na+-K+ ATPase a1 in lung cancer tumors and colon cancer tumors (D to F): Proteins were isolated from the tumors
and Western blot was performed for analysis of Na+-K+ ATPase a1 expression. Expression of Na+-K+ ATPase a1 in lung cancer tumor in rats (D)
and in A549 cells and in the lung cancer tumor from hypoxia-pretreated A549 cells in mice (E). (F) Na+-K+ ATPase a1 expression in colon cancer
tumor in rats (F). n = 3 for each group. Upper panels show representative images and lower panels show quantitative data, setting normoxia as
1. *p < 0.05 as compared with normoxia.
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mice, further demonstrating that hypoxia is not a prolif-
erative factor for the lung cancer tumor growth.
Hypoxia promotion of tumor progression in vivo has
been found in other studies when different types of can-
cers have been studied [22-29], but the results have var-
ied. Rofstad et al. found that hypoxia increased tumor
progression of D12 and R-18 melanoma, including lung
and lymph node metastasis in mice [22,23]. Zhang and
co-workers [24] found increased lung metastasis of
human fibriosarcoma from the cells pretreated with low
oxygen in mice. Buchle and colleagues [25] found that
tumor hypoxia influenced the number of metastatic
lesions, but not the tumor volume in an orthotopic
murine model for pancreatic cancer. Carines et al.
[27,28] found that acute exposure to hypoxia signifi-
cantly increased the number of positive lymph nodes,
but not the lung metastasis nodules in human cervical
carcinoma cell line (ME-180) in mice. A study by Kallio-
maki et al. did not show significant change in lung
metastasis of breast cancer in a transgenic mouse model
[30]. In the present study, we used a rat orthotopic
model of lung cancer to investigate lymphatic metastasis
and a mouse model of Lewis lung carcinoma to study
lung metastasis. We did not find any stimulating effect
of hypoxia on either lymph node metastasis or lung
metastasis. Our data thus indicated that hypoxia was
also not a stimulating factor for metastasis of lung
cancer.
We not only found decreased growth of lung cancer
tumor in vivo, but also similar results in vitro in the
growth of cultured lung cancer cells and in changes of
proliferation markers in the tumor tissues. Hypoxia-
induced inhibition of tumor progression of the lung
cancer may be via an influence on Na+-K+ ATPae. Pre-
vious studies have discovered impairment of Na+-K+
pump function and of Na+-K+ ATPase in lung alveolar
type II cells [41,42]. Heerlein et al. [43] recently found
that hypoxia exposure significantly decreased Na+-K+
ATPase related oxygen consumption and indicated that
inhibition of the Na+-K+ ATPase by hypoxia contributed
Figure 9 HIF expression and microvessel density in lung and colon cancer tumors.(A to C) Expression of HIF1a and 2a: Proteins were
isolated from lung cancer tumors and colon cancer tumors and Western blot was performed for analysis of HIF expression. (A) Expression HIF1a
mRNA and protein in lung cancer tumor; (B) Expression HIF1a in colon cancer tumor and (C) Expression of HIF2a protein in lung and colon
cancer tumors. Left panels show quantitative data, setting normoxia as 1, and right panels show representative images of Western blot. n = 3 for
each group. *p < 0.05 as compared with normoxia group. (D & E) Microvessel density: Immunohistochemical staining with CD31 antibody was
performed to identify microvessels. Microvessel density in lung cancer tumors (D) and in colon cancer tumors (E). Left panels show quantitative
data and right panels show representative images of immunohistochemistry (tumor from rats). Tumor = implanted tumor grown in rats. H-P-
tumor = tumor from hypoxia-pretreated cancer cells grown in mice. Per HFP = average number of microvessels with CD31 positive staining/per
high power field (× 200). n = 3 animals for each group. *p < 0.05 as compared with normoxia group.
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little to energy preservation in hypoxia. Hypoxia-induced
inhibition of Na+-K+ ATPase has been associated with
promoting endocytosis of Na+-K+ ATPase [44,45]. Mija-
tovic et al. [46] found an increase in expression of Na
+-K+ATPase a1 subunit in clinical samples from
patients with non small cell lung carcinoma as com-
pared with normal lung tissues. They also observed that
reduction of Na+-K+ ATPase a1 expression by a siRNA
in A549 cells resulted in markedly decreased prolifera-
tion of the cells. In addition, Xu et al. [47] recently
reported that the expression of Na+-K+ ATPase a1 was
higher in human hepatocellular carcinoma than in nor-
mal liver tissues and that a siRNA for Na+-K+ ATPase
a1 inhibited proliferation of human HepG2 liver cancer
cells. To demonstrate if hypoxia-induced inhibition of
the lung cancer tumor progression was involved in Na
+-K+ ATPase dysfunction, we investigated expression of
Na+-K+ ATPase a1 subunit, which has been used as a
marker of Na+-K+ ATPase, in the lung cancer tumors.
We found significantly decreased expression of Na+-K+
ATPase a1 not only in the lung cancer tumor from the
rats exposed to hypoxia, but also in the tumor from
hypoxia-pretreated A549 cells in mice. Because the mice
with the tumor from hypoxia-pretreated cancer cells
were housed under normoxia, this result indicated con-
tinued inhibition of Na+-K+ ATPase expression by
hypoxia; even after the tumor grew under normoxia for
3 weeks. These results demonstrated that hypoxia-
induced inhibition of tumor progression of the lung
cancer in animals was associated with a decrease in Na
+-K+ ATPase, which might result in a decrease in oxy-
gen consumption and consequently in inhibition of cell
functions, including cell division. Interestingly, the
expression of Na+-K+ ATPase a1 in colon cancer tumor
was not significantly changed under hypoxia, which
might be one of the reasons that the growth of colon
cancer tumor was not inhibited under hypoxia.
Hypoxia-inducible factors (HIF1a and HIF2a) mediate
cellular response to hypoxia, which are usually induced
under hypoxic condition. Over expression of HIF1a has
been thought to be positively related to tumor progres-
sion. However, we found a significant increase in HIF1a
protein expressions in hypoxic lung and colon cancer
tumors, but the tumor progression of lung cancer was
repressed. Actually, conflicting results have been
observed in other investigations although mainstream
research has shown that HIF1a promotes tumor pro-
gression. Volm et al. found that patients with HIF1a-
positive non-small cell lung carcinoma had significantly
longer median survival times than those patients with
HIF1a-negative carcinoma [48]. Beasley and colleagues
reported that expression of HIF1a in surgically treated
patients with head and neck squamous cell carcinoma
was associated with improved disease-free survival and
overall survival [49]. Fiorenzo et al. recently reported
that inhibition of the HIF1a by RNA interference did
not decrease tumor growth in human glioblastoma mul-
tiforme cells [50]. Besides HIF1a, we also found
increased expression of HIF2a in the lung cancer
tumor. However, no HIF2a expression was detected in
the colon cancer tumor from HCT116 cells. HIF2a has
been reported to play a similar role to HIF1a. However,
Imamura et al. recently reported different result. They
found that deficiency of HIF2a stimulated SW480 colon
cancer cell tumor growth and suggested that HIF2a
appeared to restrain tumor growth [51]. An absent or
minimal expression of HIF2a under hypoxia was
observed in other colon cancer cells [51]. Therefore, the
absent expression of HIF2a might be another reason
that long-term exposure to hypoxia enhanced the
growth of colon cancer tumor. In addition, it has been
thought that over expression of HIF1a and HIF2a is
positive related to tumor angiogenesis. We thus exam-
ined microvessel density in both lung and colon cancer
tumors and found significantly reduced microvessel den-
sity in lung cancer tumor. However, significantly
increased microvessel density in colon cancer tumor
was observed. Therefore, HIF1a and HIF2a may be
playing different roles in the progression of lung cancer
tumor and colon cancer tumor during hypoxia.
This study demonstrated that long-term exposure to
hypoxia suppressed lung tumor progression in different
animal models and found a decrease in Na+-K+ ATPase
expression in hypoxic lung cancer tumors. However,
some limitations have to be pointed out. For example,
we only used A549 cell line and HCT116 cell line; and
the precise relationship between the hypoxia-induced
expressions of HIFs and the down regulation of Na+-K+
ATPase has not been determined. Because HIF is the
major mediator in cellular adaption to hypoxia,
increased HIF1a and HIF2a might be involved in med-
iating the endocytosis of Na+-K+ ATPase. However, a
recent study [52] showed that von Hippel Lindau pro-
tein (pVHL) participated in hypoxia-mediated degrada-
tion of plasma member of Na+-K+ ATPase, but knock
down HIF1a and HIF2a by shRNA did not prevent Na
+-K+ ATPase degradation in A549 cells during hypoxia,
which suggested that HIFs were not required for Na+-K
+ ATPase degradation. In addition, we do not know why
lung cancer cells and colon cancer cells respond to
hypoxia so differently. It might be possible that lung
cells, instructed to resist relatively high and oscillating
PO2 in the alveoli, are less hypoxia-sensitive than colon
cancer cells, which would shift the balance between pro-
cancer (HIF expression) and anti-cancer (apoptosis,
endocytosis) mechanisms toward anti-cancer, whereas
the same degree of hypoxia shifts the same balance to
the other end in cells instructed to live in relatively
Yu and Hales BMC Cancer 2011, 11:331
http://www.biomedcentral.com/1471-2407/11/331
Page 13 of 15
more hypoxic environments. Those questions will be the
subject of our future work.
Conclusions
In summary, we in this study found that long-term
exposure to hypoxia significantly inhibited tumor pro-
gression of lung cancer in animals and significantly
decreased Na+-K+ ATPase a1 expression in the tumors.
This study demonstrated that hypoxia is not a promot-
ing factor for tumor progression of lung cancer from
A549 cells and that decreased expression of Na+-K+
ATPase may be involved in hypoxic inhibition of tumor
progression of the lung cancer. The results from this
study provide new insights into the role of hypoxia in
tumor progression and therapeutic strategies for cancer
treatment,
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